teprenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonists 2596 6809-52-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tetraprenylacetone
  • tetraprenyl acetone
  • teprenone
  • geranylgeranylacetone
  • selbex
; RN given refers to isomeric cpd without isomeric designation; mixture of (5E,9E,13E) & (5Z,9E,13E)-isomers
  • Molecular weight: 330.56
  • Formula: C23H38O
  • CLOGP: 7.92
  • LIPINSKI: None
  • HAC: 1
  • HDO: 0
  • TPSA: 17.07
  • ALOGS: -5.32
  • ROTB: 12

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PLK1,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 58
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 86.08 25.35 38 2937 46250 90579222
Interstitial lung disease 76.31 25.35 41 2934 76364 90549108
Platelet count decreased 63.43 25.35 45 2930 136924 90488548
Renal impairment 51.95 25.35 36 2939 105385 90520087
Anaemia 49.02 25.35 59 2916 352743 90272729
Upper respiratory tract inflammation 47.14 25.35 12 2963 2660 90622812
White blood cell count decreased 45.16 25.35 40 2935 167069 90458403
Cerebral haemorrhage 38.61 25.35 20 2955 34502 90590970
Aspartate aminotransferase increased 32.59 25.35 27 2948 102910 90522562
Gamma-glutamyltransferase increased 31.36 25.35 18 2957 37934 90587538
Alanine aminotransferase increased 31.29 25.35 28 2947 118310 90507162
Osteonecrosis of jaw 30.86 25.35 18 2957 39085 90586387
Cardiac failure 29.13 25.35 26 2949 109470 90516002
Pyrexia 27.26 25.35 64 2911 660421 89965051

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count decreased 51.23 23.27 51 2445 138530 42480309
Hepatic function abnormal 49.11 23.27 33 2463 51534 42567305
Anaemia 41.35 23.27 65 2431 280213 42338626
Decreased appetite 40.52 23.27 53 2443 193084 42425755
Inappropriate antidiuretic hormone secretion 29.89 23.27 16 2480 16525 42602314
C-reactive protein increased 28.36 23.27 26 2470 63534 42555305
Liver disorder 27.64 23.27 21 2475 39623 42579216
White blood cell count decreased 25.78 23.27 32 2464 110364 42508475
Neutrophil count decreased 24.58 23.27 24 2472 63391 42555448

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 126.50 20.95 71 5781 89224 110494223
Platelet count decreased 108.70 20.95 93 5759 230350 110353097
Anaemia 81.74 20.95 121 5731 546965 110036482
Interstitial lung disease 77.65 20.95 62 5790 139272 110444175
White blood cell count decreased 66.84 20.95 71 5781 229319 110354128
Renal impairment 59.67 20.95 61 5791 188384 110395063
Upper respiratory tract inflammation 56.31 20.95 17 5835 4354 110579093
Hyperuricaemia 45.97 20.95 20 5832 14511 110568936
Neutrophil count decreased 45.43 20.95 43 5809 120898 110462549
Cerebral haemorrhage 40.68 20.95 31 5821 64937 110518510
Decreased appetite 40.27 20.95 82 5770 475764 110107683
Pyrexia 38.18 20.95 119 5733 898146 109685301
Inappropriate antidiuretic hormone secretion 37.54 20.95 23 5829 33828 110549619
Drug eruption 36.70 20.95 27 5825 53632 110529815
Disseminated intravascular coagulation 35.74 20.95 24 5828 41262 110542185
Enterocolitis 35.01 20.95 18 5834 18931 110564516
Liver disorder 34.43 20.95 40 5812 142203 110441244
Drug ineffective 34.36 20.95 19 5833 1520521 109062926
Gamma-glutamyltransferase increased 33.50 20.95 27 5825 61282 110522165
Cerebral infarction 33.03 20.95 25 5827 51813 110531634
Fatigue 32.43 20.95 12 5840 1215946 109367501
Erythema multiforme 30.43 20.95 17 5835 21080 110562367
Gastric ulcer haemorrhage 29.04 20.95 13 5839 10081 110573366
Alanine aminotransferase increased 27.80 20.95 41 5811 183732 110399715
Haemoglobin decreased 27.37 20.95 48 5804 248679 110334768
Osteonecrosis of jaw 25.92 20.95 21 5831 47996 110535451
Pneumonia 25.82 20.95 103 5749 876611 109706836
Malignant neoplasm progression 25.05 20.95 38 5814 174529 110408918
Gastric cancer 24.90 20.95 12 5840 10996 110572451
Aspartate aminotransferase increased 24.65 20.95 36 5816 159900 110423547
Cardiac failure 24.36 20.95 39 5813 187587 110395860
Colon cancer 23.04 20.95 13 5839 16430 110567017
C-reactive protein increased 22.61 20.95 41 5811 217878 110365569
Haemorrhage subcutaneous 22.12 20.95 9 5843 5530 110577917
Spinal compression fracture 21.68 20.95 13 5839 18379 110565068
Constipation 21.64 20.95 54 5798 357732 110225715

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A02BX15 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
MeSH PA D000897 Anti-Ulcer Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D005765 Gastrointestinal Agents
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:49201 anti-ulcer drug
CHEBI has role CHEBI:62868 hepatoprotective agent
CHEBI has role CHEBI:63726 neuroprotective agent
CHEBI has role CHEBI:76595 nephroprotective agent
CHEBI has role CHEBI:77307 cardioprotective agent
CHEBI has role CHEBI:78606 Hsp70 inducer

Related Drugs by ATC class:

A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 15 drugs
acetoxolonealginic acidbismuth subcitratebismuth subnitratecarbenoxolonegefarnateirsogladinemethiosulfonium chloridepirenzepineproglumiderebamipidesucralfate show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01827 KEGG_DRUG
3796-63-2 SECONDARY_CAS_RN
C0061231 UMLSCUI
CHEBI:31649 CHEBI
CHEMBL5314356 ChEMBL_ID
DB15955 DRUGBANK_ID
5282199 PUBCHEM_CID
C031049 MESH_SUPPLEMENTAL_RECORD_UI
5412 INN_ID
S8S8451A4O UNII
1362746 RXNORM
S8S8451A4O INXIGHT DRUGS

Pharmaceutical products:

None